No Data
Jin Huo 30th Anniversary Series Event | Longde Health Industry Park Grand Opening, Jin Huo Writes a New Chapter in the Health Industry.
On November 26, 2024, the grand opening ceremony of the Kingworld-Longde Health Industry Park was held in Shenzhen, marking the beginning of the 30th anniversary celebration of Kingworld Group. On the same day, the new product 'Foci-Kingworld Angong Niuhuang Pills' jointly launched by Foci and Kingworld was also listed and debuted, a series of milestone celebration activities indicating Kingworld Pharmaceuticals' confidence and determination to continue to write a new chapter in the medical and health industry. After four years of hard work, the Longde Park creates a new business card for Longgang Health. The Longde Health Industry Park is developed by Kingworld Pharmaceuticals (01110.HK) in accordance with the national health industry development strategy combined with the industrial development plans of Shenzhen and Longgang District.
Yixintang Pharmaceutical (002727.SZ): Yixintang in Sichuan plans to invest 0.368 billion yuan to construct a large health smart medicine base logistics center project.
On November 26, Yixintang Pharmaceutical (002727.SZ) announced that, according to the company's global strategy and business positioning, in order to improve the logistics distribution capabilities in Sichuan province and meet future development needs, the company has approved its wholly-owned subsidiary, Sichuan Yixintang Pharmaceutical Co., Ltd. (hereinafter referred to as "Sichuan Yixintang"), to invest 0.368 billion yuan in Chengdu, Sichuan province to construct a large health smart medical logistics center project. The construction of the new logistics center is intended to meet the business development needs of the company in the Sichuan-Chongqing region.
Express News | Sichuan Kelun Pharmaceutical established a big health industry company in Zhejiang with a registered capital of 20 million yuan.
Universal Health International Unit Buys Stake in Hollow Capsule Manufacturer
Uni Health (02211.HK) sells capsule production business at a price of 43 million RMB.
Uni Health (02211.HK) announced the complete sale of capsule production business to an independent third party - 43.78% equity of Jilin Jintiandi Uni Health Group, for a cash consideration of RMB 43 million. The net proceeds will be used for general operating funds.
Uni health (02211.HK) intends to sell a 43.78% stake in Jilin Jintian Uni Health Group for 43 million yuan.
On November 19, 2023, uni health (02211.HK) announced that on November 19, 2024, the seller (Heilongjiang Jintian Aixin Pharmaceutical Distribution Co., Ltd.) (an indirectly wholly-owned subsidiary of the company) entered into an equity transfer agreement with the buyer (Huang Yanling), according to which the seller conditionally agreed to sell, and the buyer conditionally agreed to acquire 43.78% of the equity of the target company Jilin Jintian Uni Health Group Capsule Co., Ltd., for a consideration of 43 million yuan, but it is subject to the terms of the equity transfer agreement. After the completion of the sale, the company will no longer hold any equity in the target company.
No Data
No Data